150 related articles for article (PubMed ID: 8499642)
1. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro.
Portier M; Zhang XG; Caron E; Lu ZY; Bataille R; Klein B
Blood; 1993 Jun; 81(11):3076-82. PubMed ID: 8499642
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro.
Jernberg-Wiklund H; Pettersson M; Nilsson K
Eur J Haematol; 1991 Apr; 46(4):231-9. PubMed ID: 1826658
[TBL] [Abstract][Full Text] [Related]
3. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease.
Hitzler JK; Martinez-Valdez H; Bergsagel DB; Minden MD; Messner HA
Blood; 1991 Oct; 78(8):1996-2004. PubMed ID: 1912582
[TBL] [Abstract][Full Text] [Related]
4. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.
Jelinek DF; Aagaard-Tillery KM; Arendt BK; Arora T; Tschumper RC; Westendorf JJ
J Clin Invest; 1997 Feb; 99(3):447-56. PubMed ID: 9022078
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma in multiple myeloma.
Palumbo A; Bruno B; Boccadoro M; Pileri A
Leuk Lymphoma; 1995 Jul; 18(3-4):215-9. PubMed ID: 8535185
[TBL] [Abstract][Full Text] [Related]
6. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y
Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126
[TBL] [Abstract][Full Text] [Related]
7. [Cytokines and lymphoplasmocytic proliferations: essential role of interleukin 6].
Bataille R; Klein B
Rev Prat; 1993 Feb; 43(3):275-8. PubMed ID: 8502954
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Lu ZY; Zhang XG; Rodriguez C; Wijdenes J; Gu ZJ; Morel-Fournier B; Harousseau JL; Bataille R; Rossi JF; Klein B
Blood; 1995 May; 85(9):2521-7. PubMed ID: 7727780
[TBL] [Abstract][Full Text] [Related]
9. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines.
Spets H; Georgii-Hemming P; Siljason J; Nilsson K; Jernberg-Wiklund H
Blood; 1998 Oct; 92(8):2914-23. PubMed ID: 9763578
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?
Kovacs E
Leuk Res; 2010 Jul; 34(7):912-6. PubMed ID: 19762082
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines.
Jernberg H; Pettersson M; Kishimoto T; Nilsson K
Leukemia; 1991 Mar; 5(3):255-65. PubMed ID: 1707469
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells.
Urashima M; Teoh G; Chauhan D; Hoshi Y; Ogata A; Treon SP; Schlossman RL; Anderson KC
Blood; 1997 Jul; 90(1):279-89. PubMed ID: 9207463
[TBL] [Abstract][Full Text] [Related]
13. Growth control mechanisms in multiple myeloma.
Hawley RG; Berger LC
Leuk Lymphoma; 1998 May; 29(5-6):465-75. PubMed ID: 9643560
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
15. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
Schwabe M; Brini AT; Bosco MC; Rubboli F; Egawa M; Zhao J; Princler GL; Kung HF
J Clin Invest; 1994 Dec; 94(6):2317-25. PubMed ID: 7989587
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells.
Palumbo A; Battaglio S; Napoli P; Omedè P; Fusaro A; Bruno B; Boccadoro M; Pileri A
Br J Haematol; 1994 Apr; 86(4):726-32. PubMed ID: 7918064
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.
Zhang XG; Bataille R; Widjenes J; Klein B
Cancer; 1992 Mar; 69(6):1373-6. PubMed ID: 1540875
[TBL] [Abstract][Full Text] [Related]
18. Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells.
Usui E; Nishii K; Katayama N; Lorenzo V F; Chen F; Monma F; Otsuki T; Shiku H
Hematol J; 2004; 5(6):505-12. PubMed ID: 15570293
[TBL] [Abstract][Full Text] [Related]
19. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal-cell carcinoma.
Gruss HJ; Brach MA; Mertelsmann RH; Herrmann F
Int J Cancer; 1991 Nov; 49(5):770-3. PubMed ID: 1937963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
